WuXi ATU and Wugen Announce Manufacturing Partnership to Expedite the Delivery of Novel Cell Cancer Immunotherapies

16 June 2022 | Thursday | News


WuXi ATU's integrated CTDMO platform enables the development of WU-NK-101 by leveraging the company's Good Manufacturing Process (GMP) cell therapy manufacturing and testing capabilities to support regulatory filings and clinical trials.
Image Source : Public Domain

Image Source : Public Domain

WuXi Advanced Therapies (WuXi ATU), a global Contract Testing, Development and Manufacturing Organization (CTDMO), and Wugen Inc., a clinical-stage biotechnology company based in St. Louis and San Diego, today announced a partnership to produce Wugen's WU-NK-101, a novel immunotherapy that harnesses the power of memory natural killer (NK) cells to treat cancers. WuXi ATU will provide manufacturing and testing services for WU-NK-101 to enable the delivery of this innovative cell therapy product to cancer patients.

Wugen aims to develop a pipeline of off-the-shelf cell therapy products to treat a broad range of hematological and solid tumor malignancies. As Wugen's first program from the company's proprietary MonetaTM platform, WU-NK-101 leverages the hyper-functional, long-lasting anti-tumor functionality of memory NK cells to manufacture next-generation, off-the-shelf cancer cell therapies at commercial scale. WU-NK-101 is currently in development to treat acute myelogenous leukemia (AML) and solid tumors.

WuXi ATU's integrated CTDMO platform enables the development of WU-NK-101 by leveraging the company's Good Manufacturing Process (GMP) cell therapy manufacturing and testing capabilities to support regulatory filings and clinical trials.

"We are delighted to partner with WuXi ATU," said Dr. Dan Kemp, President and Chief Executive Officer of Wugen. "With WuXi ATU's cell therapy manufacturing expertise, integrated GMP manufacturing and testing capabilities, we can keep advancing our allogeneic WU-NK-101 program into clinical trials and accelerate the timeline for delivering convenient, effective therapeutics to patients."

"The development of allogeneic NK cell therapies is a significant step towards accelerating the progress of these innovative cancer therapeutics into the clinical pipeline," said Dr. David Chang, Chief Executive Officer of WuXi ATU. "We're delighted to partner with Wugen to help make these life-saving cancer treatments less challenging to produce and more accessible to patients in need."

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close